Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 970Neoplasms 767Carcinoma, Non-Small-Cell Lung 750Prostatic Neoplasms 577Colorectal Neoplasms 503Lung Neoplasms 447Neoplasm Metastasis 408Multiple Myeloma 376Leukemia, Myeloid, Acute 358Ovarian Neoplasms 311Pancreatic Neoplasms 306Melanoma 275Squamous Cell Carcinoma of Head and Neck 259Recurrence 248Carcinoma, Hepatocellular 233Glioblastoma 225Brain Neoplasms 221Head and Neck Neoplasms 202Triple Negative Breast Neoplasms 200Carcinoma, Renal Cell 200Lymphoma 192Precursor Cell Lymphoblastic Leukemia-Lymphoma 191Stomach Neoplasms 189Endometrial Neoplasms 179Lymphoma, Non-Hodgkin 175Sarcoma 169Glioma 168Uterine Cervical Neoplasms 167Lymphoma, Large B-Cell, Diffuse 160Hematologic Neoplasms 159

Interventions

sparsentan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Proteinuria × 90 days × Clear all
NCT07224776 2026-05-18

Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria

Brigham and Women's Hospital

Phase 1 Not yet recruiting
20 enrolled

Neoplasms, Proteinuria

NCT07561957 2026-05-01

A Smart Phone Application to Improve Adoption of the 2024 Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease (CKD) Guidelines

St. James's Hospital, Ireland

Phase NA Recruiting
80 enrolled
Genitourinary

Kidney Diseases, Nephrotic Syndrome, Proteinuria, Tuberous Sclerosis, Renal Insufficiency, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡